Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Enveric Biosciences Enveric Biosciences Announces Broad Range of Patent Issuances November 04, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 October 15, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop September 26, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit September 25, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 04, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions August 13, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results August 12, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally July 25, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement July 15, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Announces Patent Granted for Drug Candidate July 10, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate June 25, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences to Participate in BIO International Convention 2024 May 30, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results May 15, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders May 14, 2024 From Enveric Biosciences Via Business Wire Tickers CSE:MBIO ENVB Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids May 08, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 March 26, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease March 19, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets March 12, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds February 29, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property February 23, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders February 21, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series January 03, 2024 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market December 29, 2023 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series December 28, 2023 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 December 27, 2023 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024” December 20, 2023 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds December 05, 2023 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives November 29, 2023 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry November 27, 2023 From Enveric Biosciences Via Business Wire Tickers ENVB Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023) November 24, 2023 From Enveric Biosciences Via Business Wire Tickers ENVB Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
